Related Experiment Video

Updated: May 25, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Monoclonal antibodies and Fc fragments for treating solid tumors

Andrea M Eisenbeis1, Stefan J Grau

  • 1Department of Neurosurgery, University Hospital of Cologne, Cologne, Germany.

Biologics : Targets & Therapy
|February 1, 2012
PubMed

Insights

Monoclonal antibodies and Fc fragments are increasingly used in oncology for solid tumor treatment. This review covers approved therapies, their mechanisms, clinical use, and ongoing research for cancer patients.

Area of Science:

  • Biotechnology and Medicine
  • Oncology
  • Immunotherapy

Background:

  • Advances in biotechnology and understanding of disease processes have led to new therapeutic agents.
  • Molecular markers are increasingly identified, aiding targeted treatments.
  • Monoclonal antibodies and Fc fragments are now widely used in medicine, particularly in oncology.

Purpose of the Study:

  • To review currently approved monoclonal antibodies for solid tumor treatment.
  • To focus on clinical applications and biological mechanisms.
  • To summarize ongoing clinical trials in this area.

Main Methods:

  • Literature review of approved monoclonal antibodies.
  • Analysis of clinical application data.
  • Summary of biological background and ongoing trials.

Main Results:

  • Identification of key monoclonal antibodies approved for solid tumors.
  • Overview of their clinical efficacy and safety profiles.
  • Compilation of data on current research and development.

Conclusions:

  • Monoclonal antibodies represent a significant advancement in solid tumor treatment.
  • Understanding their biological basis is crucial for effective clinical application.
  • Ongoing trials promise further improvements in cancer therapy.
Keywords:
biological therapycancermonoclonal antibodiestargeted therapy

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...